Bagsværd, Denmark, 30 November 2022 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programm
Until that day, companies in the healthcare sector that can stay ahead of the curve will continue to thrive. Although this market is competitive, the company made its name by targeting the life sciences industry. In other words, Veeva Systems is a specialist, not a generalist.
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.